However, aberrant EGFR activation is frequently reported in diverse human malignancies, including NSCLC, and dysregulation of EGFR is associated with worse clinical outcomes such as a reduced survival rate, frequent metastasis to other organ, and poor chemosensitivity.8, 9, 10. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.